Heart-type fatty acid-binding protein: an overlooked cardiac biomarker. (16th November 2020)

• Record Type: Journal Article
• Authors: Goel, Harsh; Melot, Joshua; Krinock, Matthew D.; Kumar, Ashish; Nadar, Sunil K.; Lip, Gregory Y. H.
• Is Part Of: Annals of medicine. Volume 52:Number 8(2020)
• Page Start: 444
• Page End: 461
• Publication Date: 2020-11-16
• Subjects: HFABP -- heart-type fatty acid-binding protein -- review -- acute coronary syndrome -- troponin -- congestive heart failure -- prognosis; Medicine -- Periodicals; 610
• DOI: 10.1080/07853890.2020.1800075
• Languages: English
• ISSNs: 0785-3890

Abstract

Abstract: Cardiac troponins (cTn) are currently the standard of care for the diagnosis of acute coronary syndromes (ACS) in patients presenting to the emergency department (ED) with chest pain (CP). However, their plasma kinetics necessitate a prolonged ED stay or overnight hospital admission, especially in those presenting early after CP onset. Moreover, ruling out ACS in low-risk patients requires prolonged ED observation or overnight hospital admission to allow serial measurements of c-Tn, adding cost. Heart-type fatty acid-binding protein (H-FABP) is a novel marker of myocardial injury with putative advantages over cTn. Being present in abundance in the myocellular cytoplasm, it is released rapidly (<1 h) after the onset of myocardial injury and could potentially play an important role in both earlier diagnosis of high-risk patients presenting early after CP onset, as well as in risk-stratifying low-risk patients rapidly. Like cTn, H-FABP also has a potential role as a prognostic marker in other conditions where the myocardial injury occurs, such as acute congestive heart failure (CHF) and acute pulmonary embolism (PE). This review provides an overview of the evidence examining the role of H-FABP in early diagnosis and risk stratification of patients with CP and in non-ACS conditions associated with myocardial injury. Key messages: Heart-type fatty acid-binding protein is a biomarker that is elevated early in myocardial injury The routine use in the emergency department complements the use of troponins in ruling out acute coronary syndromes in patients presenting early with chest pain It also is useful in risk stratifying patients with other conditions such as heart failure and acute pulmonary embolism.